Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice

Sponsor
Multinational Center for Quality of Life Research, Russia
Study ID
NCT05566535
Status
Unknown

Conditions

  • Polycythemia Vera

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    Ruxo will be administered to patients with PV in a real-world setting. Treatment with Ruxo is according to local approved label. Ruxo treatment should be administered according to drug official instruction and in compliance with clinical practice at the certain medical center.

Study Details

The purpose of this multicenter observational prospective cohort study is to examine changes in QoL and symptoms in patients with polycythemia vera (PV) during treatment with ruxolitinib (Ruxo), and to evaluate efficacy and safety of Ruxo in a real-world setting

Key Dates

Start date
Oct 1, 2022
Status verified
Sep 2022
Primary completion
May 1, 2024
Completion
Aug 1, 2024

Study Design

Enrollment
32 participants (estimated)

Primary Outcome Measure

Change From Baseline in QoL as per SF-36 questionnaire domains at 3 and 9 months of Ruxo treatment [ Time Frame: Baseline, 3 and 9 months of Ruxo treatment ]

Central Contacts

Related Studies